Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

470.85INR
23 Apr 2014
Price Change (% chg)

Rs5.90 (+1.27%)
Prev Close
Rs464.95
Open
Rs463.55
Day's High
Rs483.10
Day's Low
Rs463.55
Volume
3,615,068
Avg. Vol
4,048,410
52-wk High
Rs490.00
52-wk Low
Rs253.65

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 1.35
Market Cap (Mil.): Rs197,048.50
Shares Outstanding (Mil.): 423.81
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 33.12 33.26
EPS (TTM): -23.92 -- --
ROI: -13.83 19.69 18.95
ROE: -26.67 20.39 19.72
Search Stocks

India regulator examines Sun, Ranbaxy merger trading: source

MUMBAI - India's market regulator will ask Ranbaxy Laboratories and Sun Pharmaceutical Industries for more information about their planned $3.2 billion merger and seek trading data from stock exchanges after shares in Ranbaxy surged in the run-up to the deal, a senior source at the regulator said on Wednesday.

09 Apr 2014

Europe's regulator to inspect Ranbaxy's India plant in June

MUMBAI - Europe's drug regulator said on Wednesday an inspection of Indian generic drugmaker Ranbaxy Laboratories Ltd's Dewas plant in India is planned for June, amid concerns about its production processes after a spate of regulatory sanctions.

09 Apr 2014

Europe's regulator to inspect Ranbaxy's India plant in June

MUMBAI, April 9 - Europe's drug regulator said on Wednesday an inspection of Indian generic drugmaker Ranbaxy Laboratories Ltd's Dewas plant in India is planned for June, amid concerns about its production processes after a spate of regulatory sanctions.

09 Apr 2014

UPDATE 2-India regulator examines Sun, Ranbaxy merger trading - source

* SEBI to ask Sun Pharma, Ranbaxy for information on merger

09 Apr 2014

India's Sun Pharma plans gradual phase-out of Ranbaxy-branded drugs in U.S.: sources

MUMBAI - India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States, after completing a $3.2 billion takeover of its loss-making rival by the year end, sources with direct knowledge of the matter said.

09 Apr 2014

UPDATE 2-India's Sun Pharma plans gradual phase-out of Ranbaxy-branded drugs in US -sources

* European regulator plans Ranbaxy plant inspection in June (Adds fund manager comment, European regulator comments)

09 Apr 2014

India's Sun Pharma plans gradual phase-out of Ranbaxy-branded drugs in US -sources

MUMBAI, April 9 - India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a $3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.

09 Apr 2014

Update-Moody's: Daiichi Sankyo Will Benefit from Sun Pharma's Acquisition of Ranbaxy

Sun Pharmaceutical Industries Ltd (Sun Pharma) & Ranbaxy Laboratories Ltd (Ranbaxy)

09 Apr 2014

India's Sun Pharma to buy struggling Ranbaxy for $3.2 billion as Daiichi Sankyo retreats

TOKYO/MUMBAI - India's Sun Pharmaceutical Industries Ltd has agreed to buy generic drugmaker Ranbaxy Laboratories Ltd for $3.2 billion, betting it can fix factory quality glitches that plagued the current owner, Japan's Daiichi Sankyo Co , and got Ranbaxy India-made drugs barred from the United States. | Video

07 Apr 2014

India's Sun Pharma expects Ranbaxy business to be profitable in short term

MUMBAI - India's Sun Pharmaceutical Industries Ltd Managing Director Dilip Shanghvi said he expects Ranbaxy Laboratories Ltd to become profitable in the short term.

07 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks